Is Consolidation Osimertinib Superior in EGFR-Mutated NSCLC? Is Consolidation Osimertinib Superior in EGFR-Mutated NSCLC?

A retrospective study showed consolidated osimertinib after chemoradiation prolonged progression-free survival in patients with EGFR-mutated, stage III NSCLC compared with durvalumab or observation.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news